InnoCare Pharma ( $INNOCARE (09969.HK)$； $InnoCare Pharma (688428.SH)$), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first patient has been dosed in a clinical trial of the Company's BCL2 inhibitor, ICP-248, in combination with orelabrutinib as a first-line therap...

InnoCare Pharma ( $INNOCARE (09969.HK)$； $InnoCare Pharma (688428.SH)$), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of psoriasis.
This is a multicente...

InnoCare Pharma ( $INNOCARE (09969.HK)$； $InnoCare Pharma (688428.SH)$), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the release of its 2023 Environmental, Social, and Corporate Governance (ESG) report. This marks the fifth year InnoCare has issued its ESG report, and the first year InnoCare has set up specific environmental management targets.
In the...

$INNOCARE (09969.HK)$ $InnoCare Pharma (688428.SH)$ The American Journal of Hematology recently published the results of a phase II study of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in patients with patients with persistent or chronic primary immune thrombocytopenia (ITP), which evaluated the efficacy and safety of orelabrutinib in adult patients with persistent or chronic ITP. The jour...

InnoCare Pharma ( $INNOCARE (09969.HK)$ $InnoCare Pharma (688428.SH)$), a leading biopharmaceutical company announced that the first patient in China has been dosed in the Phase 1b clinical study of the combination of InnoCare’s novel SHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) allosteric inhibitor, ICP-189, with ArriVent’s furmonertin...

InnoCare Pharma ( $INNOCARE (09969.HK)$ $InnoCare Pharma (688428.SH)$), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.
Financial Highlights
•   Revenue increased by 18.1% to RMB738.5 million in 2023, including RMB670.7 million from orelabrutinib, an increase of 18.5%, mainly due to the continuous and rapid ramp-up of orelabrutinib sales.
•   Gross ...

$INNOCARE (09969.HK)$； $InnoCare Pharma (688428.SH)$

InnoCare Pharma ( $INNOCARE (09969.HK)$； $InnoCare Pharma (688428.SH)$), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor...

InnoCare Pharma ( $INNOCARE (09969.HK)$; $InnoCare Pharma (688428.SH)$), a commercial-stage biotech company, announced today that the latest data of the novel TYK2 inhibitor ICP-332 developed by the Company for the treatment of patients with moderate-to-severe atopic dermatitis (AD) has been released at the 2024 American Academy of Dermatology (AAD) Annual Meeting as a late-breaking oral ...

InnoCare Pharma ( $INNOCARE (09969.HK)$； $InnoCare Pharma (688428.SH)$), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first pediatric patient has been dosed in clinical trial with its second generation pan-TRK inhibitor zurletrectinib at Sun Yat-sen University Cancer Center. This is the first time that zurletrec...